pegIFNα-2a

DRUG2 trials

Sponsors

Janssen Pharmaceutical K.K., Bristol-Myers Squibb

Conditions

Hepatitis B VirusHepatitis C, Chronic

Phase 2

A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients

CompletedNCT00996476

Janssen Pharmaceutical K.K.Hepatitis C, Chronic

Start: 2009-07-31End: 2011-01-31Updated: 2014-04-17

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

CompletedNCT01204762

Bristol-Myers SquibbHepatitis B Virus

Start: 2010-11-30End: 2013-12-31Updated: 2015-10-09

Related Papers

Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients

Frontiers in Immunology2017-05-2967 citations

Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B).

2015-12-2984 citations

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.

2013-09-0560 citations